HIM is advancing science and bridging the gap between the bench and bedside

HIM is home to a highly collaborative group of scientists and medical doctors who work on solving fundamental questions in the fields of omics and oncology for the advancement of diagnostics and therapeutics.

HIM has set up a dozen of research centers/labs, including Aptamer Selection Center, New Medicine and Targeted Treatment Center, Intelligent Diagnosis Center, Upper Gastrointestinal Tumor Diagnosis & Treatment Center, and Joint ECMO R&D Center. In academic research, the big-team breakthrough mode based on major projects and led by academicians and leading talents is adopted, and a batch of initial achievements have been scored in fast nucleic acid diagnosis of COVID-19, ECMO equipment and targeted tumor treatment, and heavy ion R&D for cancer treatment. In the construction of coordinated and innovative system of industry, university, research and hospital, the Institute has established close cooperation with medical institutions such as Cancer Hospital of the University of Chinese Academy of Sciences, University of Macau, and Institute of Chemistry Chinese Academy of Sciences, as well as leading enterprises such as Ustar and Cobetter in Hangzhou.

Technology Development

Through strategic integration of medical schools, research institutes, and hospitals, we are able to focus on basic research and bring such research through clinical development and ultimately to patients. This integrative research model is based upon the collaborations of IBMC, Chinese Academy of Sciences, Cancer Hospital Affiliated with the Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou Institute of Advanced Studies, University of Chinese Academy of Sciences.

Established in October 1963, the Zhejiang Cancer Hospital is one of the first four cancer hospitals established in P.RC. Integrating cancer prevention, medical treatment, scientific research, teaching and rehabilitation, it undertakes the important task of national cancer prevention and plays a leading role in the national cancer prevention and treatment. It has been ranked among the top 10 oncology specialties in China for 8 consecutive years. In May 2019, the People’s Government of Zhejiang Province signed a medical cooperation agreement with the University of Chinese Academy of Sciences, and Zhejiang Cancer Hospital was officially listed as the “Institute of Cancer and Basic Medicine of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital affiliated to University of Chinese Academy of Sciences, Hangzhou Clinical Medical College of the University of Chinese Academy of Sciences.”

Instrument Platforms

Whether its basic research or late-stage tech development, our institute is built to provide the tools and expertise you need.  The platform management department is affiliated with HIM and provides professional analysis and testing, experiments and consulting services to research institutes, affiliated hospitals and research institutions. At present, the department has more than 100 kinds of scientific research equipment, including more than 60 large-scale scientific research instruments. In the future, it will develop into a large-scale integrated open platform integrating technology development, scientific research support, clinical services and industrial cooperation.

  • Animal Research
  • Bioimaging
  • Histological
  • Material Structure

Animal Research Platform

HIM’s animal experiment platform operates under national standards. All experiments involving animals are subject to stringent review. Our platform is equipped with a 1000 square meter SPF-class experimental animal facility that is mainly used for rat breeding and experiments. Furthermore, facilities are equipped with a small animal magnetic resonance imaging system, live imaging, infrared second-zone imaging, optical sound imaging, confocal microscope, blood cell analyzer, and other animal-related experiments required equipment.

In the near term, the platform will construct experimental animal breeding facilities that meet AAALC, GLP and ABSL2 standards. We will also develop a genetically engineered animal resource and biological data sharing platform. We will provide important basic support conditions for life science research and the biopharmaceutical industry.

Animal models are only one of the many model systems that biomedical research relies upon to advance new medicine and diagnostics. At HIM, models such as computer modeling, cell culture and bacterial systems are used as alternatives to animal models whenever possible.

Bioimaging Platform

The platform is equipped with large instruments such as a high-content imaging system, ultra-resolution SIM microscope, dual photon confocal microscope, turntable confocal microscope, single-molecule TIRF imaging system, and so forth. We strive to provide comprehensive micro-imaging and image analysis services. Our facilities are also equipped with flow sorting, multi-color flow analysis, nano-flow and other equipment to provide cell and molecular biology-related technical services.

Histological Research Platform

The platform is equipped with a high-resolution liquid phase mass spectrometry instrument, MALDI-TOF, ICP mass spectrometer, gas phase mass spectrometer, high-efficiency liquid chromatography, circular dichromatometer, Fourier infrared spectrometer, ultraviolet visible spectrophotometry meter, full function steady-state and transient fluorescence spectrometers, as well as other world-class experimental equipment. We provide mass spectrometry imaging, comprehensive characterization of polymers, material identification and structural analysis, and elemental analysis for pharmacy, biochemistry, clinical applications, and histological research.

Material Structure Platform

The platform is equipped with a transmission electronmicroscope, scanning electron microscope, atomic force microscope, magnetic tweezer force spectrum test system, nuclear magnetic resonance spectrometer,and other world-class experimental equipment. The platform can provide 2D/3D high-resolution imaging of materials and samples, micromorphology and composition information of samples, qualitative/quantitative analysis of crystal structure, tribology of samples, and electrical and magnetic analysis of samples.


HIM’s centers are designed with the mindset of efficiently translating laboratory developments to clinical setting to address real medical problems.

Center for Intelligent Molecular Diagnostics

The center carries out molecular diagnosis and automated detection of major diseases such as malignant tumors and major infectious diseases. The center focuses on developing precision detection technology for tumors and pathogenic microorganisms, instant intelligent detection equipment and home-type, project-based joint inspection products, building artificial intelligence and blockchain-assisted diagnosis and treatment and health management platform driven by medical big data, and improving the early warning and detection capabilities of major diseases.

Aptamer Selection Center

The center is committed to establishing high-throughput and low-cost next-generation screening technologies that can quickly generate aptamers for different targets such as small molecules, proteins, cells, body fluids, and even organs for specific needs. The center focuses on breaking through the technical bottleneck of aptamers and providing innovative research tools and a technology platform for the research of oncology and basic medicine.

Center for Innovative Drugs and Precision Theranostics

Developing novel medicine is a cornerstone of HIM. We work on addressing the technical barriers of cell therapy and develop small molecule drug candidates. We also have laboratories devoted to gastric cancer intelligent surgery and to studying proteomics.

Center for Diagnosis and Treatment of Upper Gastrointestinal Tumors

The center was officially established in 2019 under the leadership of the University-affiliated Oncology Hospital of the Chinese Academy of Sciences. The center efficiently integrates internal medicine, surgery, radiation, and chemotherapy through collaborations with the Cancer Foundation Institute, MD Anderson Cancer Institute and domestic institutes.

Joint R&D ECMO Center at HIM

The center works towards achieving safe and autonomous control, thereby reducing ECMO treatment costs, increasing performance and saving more lives. The lead unit and enterprise are responsible for the research and development and registered production of ECMO medical devices, and the hospital is responsible for the clinical verification and development of ECMO medical devices.